Uncovering the therapeutic potential of anti-tuberculoid agent Isoniazid in a model of microbial-driven Crohn's Disease.
TNFα has long stood as a hallmark feature of both inflammatory bowel disease (IBD) and arthritis with its therapeutic potential demonstrated in neutralizing monoclonal antibody treatments s...